<p>随着澳大利亚市场接近 2025 年底，尽管华尔街的指数接近历史高点，但市场似乎处于反思的状态，投资者在假期前进行获利了结，导致市场略有下滑。在这种环境下，内部持股比例高的成长型公司可能会提供吸引人的机会，因为它们在管理层与股东利益之间的潜在一致性。</p>
<h3>澳大利亚内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>Wisr (ASX:WZR)</td>
<td>10.2%</td>
<td>96.3%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>14.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Sea Forest (ASX:SEA)</td>
<td>15.1%</td>
<td>92.6%</td>
</tr>
<tr>
<td>Pointerra (ASX:3DP)</td>
<td>19.8%</td>
<td>110.3%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>IperionX (ASX:IPX)</td>
<td>17.1%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Emerald Resources (ASX:EMR)</td>
<td>18.4%</td>
<td>43%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19%</td>
<td>51.4%</td>
</tr>
<tr>
<td>BlinkLab (ASX:BB1)</td>
<td>32.1%</td>
<td>101.4%</td>
</tr>
<tr>
<td>Adveritas (ASX:AV1)</td>
<td>18.4%</td>
<td>96.8%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们内部持股比例高的快速成长 ASX 公司筛选器中的 111 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Clinuvel Pharmaceuticals (ASX:CUV)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Clinuvel Pharmaceuticals Limited 是一家生物制药公司，开发和商业化针对遗传、代谢、系统性和危及生命的疾病的治疗方案，业务覆盖澳大利亚、欧洲、美国、瑞士及国际市场，市值为 6.255 亿澳元。</p>
<p><strong>运营：</strong> 该公司在生物制药领域的收入为 9502 万澳元，专注于多个地区的各种疾病治疗。</p>
<p><strong>内部持股比例：</strong> 10.3%</p>
<p>Clinuvel Pharmaceuticals 有望实现强劲增长，预计年收益增长 23.9%，超过澳大利亚市场。尽管预计股本回报率较低，为 18.8%，但 Clinuvel 的收入预计将以每年 22% 的速度增长，超过市场平均水平。该公司的交易价格显著低于其估计的公允价值，并保持对收购的严格控制，专注于符合其风险调整回报标准的北美机会，同时确保运营韧性和战略资本部署。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 Clinuvel Pharmaceuticals 的表现。</li>
<li>根据我们的估值报告，Clinuvel Pharmaceuticals 的股价可能偏低。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 ASX:CUV 持股结构</p>
<h2>Regis Healthcare (ASX:REG)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Regis Healthcare Limited 在澳大利亚提供住宅养老服务，市值为 21 亿澳元。</p>
<p><strong>运营：</strong> 该公司在住宅养老、家庭护理和退休生活服务方面的收入为 11.6 亿澳元。</p>
<p><strong>内部持股比例：</strong> 38.6%</p>
<p>Regis Healthcare 正在寻求战略收购以扩展其投资组合，目标是在 2028 年前达到 10,000 张床位。该公司的交易价格显著低于其估计的公允价值，预计年收入增长 8.2%，超过澳大利亚市场。尽管预计收益将以每年 18.6% 的速度强劲增长，但仍低于重要水平。尽管有大量一次性项目影响财务结果，Regis 的股本回报率预计在三年内将非常高。</p>
<ul>
<li>通过我们的综合分析师估计报告，深入了解 Regis Healthcare 的复杂情况。</li>
<li>在审查我们的最新估值报告后，Regis Healthcare 的股价可能过于悲观。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ASX:REG 收益和收入增长</p>
<h2>Regal Partners (ASX:RPL)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Regal Partners Limited 是一家私营对冲基金赞助商，市值为 11.8 亿澳元。</p>
<p><strong>运营：</strong> 该公司的收入主要来自投资管理服务，金额为 2.4545 亿澳元。</p>
<p><strong>内部持股比例：</strong> 23.8%</p>
<p>Regal Partners 处于增长状态，预计年收入将增长 15.9%，超过澳大利亚市场的平均水平。该公司的收益预计将以每年 31.51% 的速度显著增长，也超出市场预期。尽管交易价格显著低于其估计的公允价值 42.2%，但利润率已从去年的水平下降。尽管预计其股本回报率在三年内将较低，但内部持股比例仍然较高，且近期没有重大交易活动。</p>
<ul>
<li>通过我们的完整分析未来增长报告深入了解 Regal Partners。</li>
<li>根据我们最近的估值报告，Regal Partners 的交易价格可能低于其估计价值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ASX:RPL 收益和收入增长</p>
<h2>接下来该怎么办？</h2>
<ul>
<li>解锁更多宝藏！我们的内部持股比例高的快速成长 ASX 公司筛选器为您挖掘了 108 家公司供您探索。点击这里揭示我们精心策划的 111 家快速成长 ASX 公司列表。</li>
<li>想要探索一些替代方案？发现 16 家在 COVID 后生存并蓬勃发展的公司，具备应对特朗普关税的正确条件。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
<p>国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

皇庭智家

<p>随着 2025 年的结束，尽管华尔街创下新高，澳大利亚市场却出现小幅下跌，投资者开始获利了结。高内部持股的成长型公司被强调为具有吸引力的投资机会。值得注意的公司包括 Wisr（10.2% 的内部持股，96.3% 的收益增长）、Titomic（14.8%，74.9%）和 Clinuvel Pharmaceuticals（10.3%，23.9% 的年增长）。Regis Healthcare（38.6% 的持股）计划到 2028 年实现 10,000 张床位，而 Regal Partners（23.8%）则预计将实现显著的收益增长。文章强调了这些公司在市场波动中的潜力，呼吁进一步探索高内部持股的股票</p>

<p>As the Australian market approaches the end of 2025, it appears to be in a reflective mood with a slight dip as investors engage in profit-taking before the holiday break, despite Wall Street's indices nearing record highs. In this environment, growth companies with high insider ownership can present appealing opportunities due to their potential for alignment between management and shareholder interests.</p>
<div class="lb-trans"><p>随着澳大利亚市场接近 2025 年底，尽管华尔街的指数接近历史高点，但市场似乎处于反思的状态，投资者在假期前进行获利了结，导致市场略有下滑。在这种环境下，内部持股比例高的成长型公司可能会提供吸引人的机会，因为它们在管理层与股东利益之间的潜在一致性。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Australia</h3>
<div class="lb-trans"><h3>澳大利亚内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Wisr (ASX:WZR)</td>
<td>10.2%</td>
<td>96.3%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>14.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Sea Forest (ASX:SEA)</td>
<td>15.1%</td>
<td>92.6%</td>
</tr>
<tr>
<td>Pointerra (ASX:3DP)</td>
<td>19.8%</td>
<td>110.3%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>IperionX (ASX:IPX)</td>
<td>17.1%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Emerald Resources (ASX:EMR)</td>
<td>18.4%</td>
<td>43%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19%</td>
<td>51.4%</td>
</tr>
<tr>
<td>BlinkLab (ASX:BB1)</td>
<td>32.1%</td>
<td>101.4%</td>
</tr>
<tr>
<td>Adveritas (ASX:AV1)</td>
<td>18.4%</td>
<td>96.8%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>Wisr (ASX:WZR)</td>
<td>10.2%</td>
<td>96.3%</td>
</tr>
<tr>
<td>Titomic (ASX:TTT)</td>
<td>14.8%</td>
<td>74.9%</td>
</tr>
<tr>
<td>Sea Forest (ASX:SEA)</td>
<td>15.1%</td>
<td>92.6%</td>
</tr>
<tr>
<td>Pointerra (ASX:3DP)</td>
<td>19.8%</td>
<td>110.3%</td>
</tr>
<tr>
<td>Newfield Resources (ASX:NWF)</td>
<td>31.5%</td>
<td>72.1%</td>
</tr>
<tr>
<td>IperionX (ASX:IPX)</td>
<td>17.1%</td>
<td>94.9%</td>
</tr>
<tr>
<td>Emerald Resources (ASX:EMR)</td>
<td>18.4%</td>
<td>43%</td>
</tr>
<tr>
<td>Echo IQ (ASX:EIQ)</td>
<td>19%</td>
<td>51.4%</td>
</tr>
<tr>
<td>BlinkLab (ASX:BB1)</td>
<td>32.1%</td>
<td>101.4%</td>
</tr>
<tr>
<td>Adveritas (ASX:AV1)</td>
<td>18.4%</td>
<td>96.8%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 111 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们内部持股比例高的快速成长 ASX 公司筛选器中的 111 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Clinuvel Pharmaceuticals (ASX:CUV)</h2>
<div class="lb-trans"><h2>Clinuvel Pharmaceuticals (ASX:CUV)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$625.50 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Clinuvel Pharmaceuticals Limited 是一家生物制药公司，开发和商业化针对遗传、代谢、系统性和危及生命的疾病的治疗方案，业务覆盖澳大利亚、欧洲、美国、瑞士及国际市场，市值为 6.255 亿澳元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$95.02 million from its biopharmaceutical sector, focusing on treatments for various disorders across multiple regions.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司在生物制药领域的收入为 9502 万澳元，专注于多个地区的各种疾病治疗。</p>
</div><p><strong>Insider Ownership:</strong> 10.3%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 10.3%</p>
</div><p>Clinuvel Pharmaceuticals is poised for robust growth, with earnings forecast to rise 23.9% annually, outpacing the Australian market. Despite a projected low Return on Equity of 18.8%, Clinuvel's revenue is expected to grow at 22% per year, surpassing market averages. The company trades significantly below its estimated fair value and maintains a disciplined approach to acquisitions, focusing on North American opportunities that align with its risk-adjusted return criteria while ensuring operational resilience and strategic capital deployment.</p>
<div class="lb-trans"><p>Clinuvel Pharmaceuticals 有望实现强劲增长，预计年收益增长 23.9%，超过澳大利亚市场。尽管预计股本回报率较低，为 18.8%，但 Clinuvel 的收入预计将以每年 22% 的速度增长，超过市场平均水平。该公司的交易价格显著低于其估计的公允价值，并保持对收购的严格控制，专注于符合其风险调整回报标准的北美机会，同时确保运营韧性和战略资本部署。</p>
</div><ul>
<li>Get an in-depth perspective on Clinuvel Pharmaceuticals' performance by reading our analyst estimates report here.</li>
<li>According our valuation report, there's an indication that Clinuvel Pharmaceuticals' share price might be on the cheaper side.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 Clinuvel Pharmaceuticals 的表现。</li>
<li>根据我们的估值报告，Clinuvel Pharmaceuticals 的股价可能偏低。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/8fdbe90e-88da-4878-b646-8c5610ec3e4c/chart/ownership-breakdown"/></p>
<p>ASX:CUV Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:CUV 持股结构</p>
</div><h2>Regis Healthcare (ASX:REG)</h2>
<div class="lb-trans"><h2>Regis Healthcare (ASX:REG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$2.10 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Regis Healthcare Limited 在澳大利亚提供住宅养老服务，市值为 21 亿澳元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$1.16 billion from its residential aged care, home care, and retirement living services in Australia.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司在住宅养老、家庭护理和退休生活服务方面的收入为 11.6 亿澳元。</p>
</div><p><strong>Insider Ownership:</strong> 38.6%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 38.6%</p>
</div><p>Regis Healthcare is targeting strategic acquisitions to expand its portfolio and aims for 10,000 beds by 2028. The company is trading significantly below its estimated fair value and expects revenue growth of 8.2% annually, outpacing the Australian market. Although earnings are forecast to grow at a robust 18.6% annually, they remain below significant levels. Despite large one-off items affecting financial results, Regis's Return on Equity is projected to be very high in three years' time.</p>
<div class="lb-trans"><p>Regis Healthcare 正在寻求战略收购以扩展其投资组合，目标是在 2028 年前达到 10,000 张床位。该公司的交易价格显著低于其估计的公允价值，预计年收入增长 8.2%，超过澳大利亚市场。尽管预计收益将以每年 18.6% 的速度强劲增长，但仍低于重要水平。尽管有大量一次性项目影响财务结果，Regis 的股本回报率预计在三年内将非常高。</p>
</div><ul>
<li>Navigate through the intricacies of Regis Healthcare with our comprehensive analyst estimates report here.</li>
<li>Upon reviewing our latest valuation report, Regis Healthcare's share price might be too pessimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合分析师估计报告，深入了解 Regis Healthcare 的复杂情况。</li>
<li>在审查我们的最新估值报告后，Regis Healthcare 的股价可能过于悲观。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/03541fc6-4c52-491d-a42d-0c4b1d7681ae/chart/earnings-and-revenue-growth"/></p>
<p>ASX:REG Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:REG 收益和收入增长</p>
</div><h2>Regal Partners (ASX:RPL)</h2>
<div class="lb-trans"><h2>Regal Partners (ASX:RPL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Regal Partners Limited is a privately owned hedge fund sponsor with a market capitalization of A$1.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Regal Partners Limited 是一家私营对冲基金赞助商，市值为 11.8 亿澳元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the provision of investment management services, amounting to A$245.45 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司的收入主要来自投资管理服务，金额为 2.4545 亿澳元。</p>
</div><p><strong>Insider Ownership:</strong> 23.8%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 23.8%</p>
</div><p>Regal Partners is positioned for growth, with revenue expected to increase by 15.9% annually, surpassing the Australian market's average. The company's earnings are forecast to grow significantly at 31.51% per year, also exceeding market expectations. Despite trading at a substantial discount of 42.2% below its estimated fair value, profit margins have declined from last year’s levels. While its Return on Equity is projected to be low in three years, insider ownership remains high without recent substantial trading activity.</p>
<div class="lb-trans"><p>Regal Partners 处于增长状态，预计年收入将增长 15.9%，超过澳大利亚市场的平均水平。该公司的收益预计将以每年 31.51% 的速度显著增长，也超出市场预期。尽管交易价格显著低于其估计的公允价值 42.2%，但利润率已从去年的水平下降。尽管预计其股本回报率在三年内将较低，但内部持股比例仍然较高，且近期没有重大交易活动。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Regal Partners.</li>
<li>In light of our recent valuation report, it seems possible that Regal Partners is trading behind its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的完整分析未来增长报告深入了解 Regal Partners。</li>
<li>根据我们最近的估值报告，Regal Partners 的交易价格可能低于其估计价值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/3a811177-0426-4731-bd9f-cb3e6afffa07/chart/earnings-and-revenue-growth"/></p>
<p>ASX:RPL Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ASX:RPL 收益和收入增长</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该怎么办？</h2>
</div><ul>
<li>Unlock more gems! Our Fast Growing ASX Companies With High Insider Ownership screener has unearthed 108 more companies for you to explore.Click here to unveil our expertly curated list of 111 Fast Growing ASX Companies With High Insider Ownership.</li>
<li>Want To Explore Some Alternatives? Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁更多宝藏！我们的内部持股比例高的快速成长 ASX 公司筛选器为您挖掘了 108 家公司供您探索。点击这里揭示我们精心策划的 111 家快速成长 ASX 公司列表。</li>
<li>想要探索一些替代方案？发现 16 家在 COVID 后生存并蓬勃发展的公司，具备应对特朗普关税的正确条件。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

2025 年 12 月 ASX 成长股中拥有高内部持股的公司